Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3



Status:Completed
Conditions:High Cholesterol
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - 80
Updated:12/1/2018
Start Date:December 10, 2013
End Date:November 21, 2017

Use our guide to learn which trials are right for you!

A Double-blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Evolocumab, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor Due to Muscle Related Side Effects

The primary objective of this study was to evaluate the effect of 24 weeks of evolocumab
administered subcutaneously (SC) every month, compared with ezetimibe, on low-density
lipoprotein cholesterol (LDL-C) levels in adults with high cholesterol who are unable to
tolerate an effective dose of a statin due to muscle-related side effects (MRSE).

The study is divided into 3 parts (A, B, C). After an initial 4-week washout period in which
any statins, ezetimibe, or other lipid-lowering agents were discontinued, participants were
enrolled in phase A, a double-blind, placebo-controlled crossover procedure to rechallenge
patients with atorvastatin. Patients were randomly assigned in a 1:1 ratio to receive either
atorvastatin (20 mg daily) or matching placebo for the first 10 weeks (period 1), then
underwent a 2-week washout period, followed by crossover to the alternate therapy for a
second 10-week period (period 2). Patients who experienced intolerable muscle symptoms during
the first period did not complete the full 10 weeks of exposure but entered a 2-week washout
period before proceeding to period 2.

Participants who did not develop muscle-related side effects were removed from the study, as
were patients who reported muscle-related side effects during a placebo period.

After completion of phase A, patients who experienced muscle-related adverse effects while
taking atorvastatin but not placebo were eligible for phase B, a 24-week, double-blind
randomization to ezetimibe or evolocumab using a double-dummy design in which patients
received either injectable placebo and oral ezetimibe or injectable evolocumab and oral
placebo. A patient could proceed directly to phase B if they had a documented history of
creatine kinase (CK) elevation more than 10 times the upper limit of normal accompanied by
muscle symptoms while taking statin therapy, with documented resolution of both CK elevation
and symptoms upon discontinuation of statin therapy.

These study procedures were designed to ensure that only patients with reproducible
statin-associated muscle symptoms entered phase B of the study. For phase B, participants
were randomized 2:1 to receive subcutaneously administered evolocumab (420 mg monthly) or
oral ezetimibe (10 mg daily). Randomization in part B was stratified by screening LDL-C level
(< 180 mg/dL [4.66 mmol/L] vs. ≥ 180 mg/dL) at study baseline.

Participants who completed phase B and did not discontinue SC investigational product for any
reason, including an adverse event, were eligible to proceed to the 2-year open-label
extension phase C to evaluate the long-term safety and efficacy of evolocumab in
statin-intolerant patients. Participants in phase C were allowed to choose quarterly between
evolocumab 420 mg SC QM or evolocumab 140 mg SC every 2 weeks (Q2W).

Inclusion Criteria:

- Male or female ≥ 18 to ≤ 80 years of age

- Subject not at LDL-C goal

- History of statin intolerance

- Lipid lowering therapy has been stable prior to enrolment for at least 4 weeks

- Fasting triglycerides ≤ 400 mg/dL

Exclusion Criteria:

- New York Heart Association (NYHA) III or IV heart failure

- Uncontrolled cardiac arrhythmia

- Uncontrolled hypertension

- Type 1 diabetes

- Poorly controlled type 2 diabetes

- Uncontrolled hypothyroidism or hyperthyroidism
We found this trial at
19
sites
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Beverly Hills, California 90211
?
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
?
mi
from
Camperdown,
Click here to add this to my saved trials
Charleston, South Carolina 29412
?
mi
from
Charleston, SC
Click here to add this to my saved trials
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
Huntington Beach, California 92646
?
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
?
mi
from
Kansas City, KS
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Rochester, MN
Click here to add this to my saved trials
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
?
mi
from
San Pedro, CA
Click here to add this to my saved trials
?
mi
from
Sterling, IL
Click here to add this to my saved trials
?
mi
from
Towson, MD
Click here to add this to my saved trials
?
mi
from
York, PA
Click here to add this to my saved trials